

## ASX Announcement

### Imugene to Present New PD1-Vaxx Data at the 2022 World Conference on Lung Cancer

---

**Sydney, Australia, 13 July 2022:** Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, announces new data from non-small cell lung cancer patients in the Phase I IMPRINTER trial has been selected for a poster presentation at the IASLC 2022 World Conference on Lung Cancer (WCLC 2022) taking place in-person and online from 6-9 August 2022 in Vienna, Austria.

The abstract for the poster is available from 6:00 pm CEST on 12 July 2022 at [wclc2022.iaslc.org](https://wclc2022.iaslc.org) and will subsequently be made available on Imugene's website at [www.imugene.com/conference-presentations](https://www.imugene.com/conference-presentations).

**Abstract Title:** Phase 1: IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy as Monotherapy or in Combination with Atezolizumab, in Adults with Non-Small Cell Lung Cancer

**Session Title:** Metastatic Non-small Cell Lung Cancer – Immunotherapy

**Session Number:** P1.15-08 **Presentation Session:** 7 August 2022, 5:00 pm – 7:00 pm CEST

**Presenting Author:** Professor Michael Boyer M.D., MBBS, FRACP, PhD, Chris O'Brien Lifehouse Hospital.

**About WCLC 2022:** WCLC is the world's largest international gathering of clinicians, researchers and scientists in the field of lung cancer and thoracic oncology. It is held by the International Association for the Study of Lung Cancer (IASLC) which is a global network of more than 8,000 lung and thoracic cancer specialists from all disciplines dedicated to the study and eradication of lung cancer and other thoracic malignancies. Visit [wclc2022.iaslc.org](https://wclc2022.iaslc.org) for more information.

Full study details can also be found on [clinicaltrials.gov](https://clinicaltrials.gov) under study ID: NCT04432207

For more information please contact:

**Leslie Chong**  
**Managing Director and Chief Executive Officer**  
[info@imugene.com](mailto:info@imugene.com)

**Investor Enquiries**  
[investor@imugene.com](mailto:investor@imugene.com)



## **Media Enquiries**

Matt Wright

[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

Follow us on Twitter @TeamImugene

Like us on Facebook @Imugene

Connect with us on LinkedIn @Imugene Limited

Watch us on YouTube @Imugene Limited

## **About Imugene (ASX:IMU)**

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

*Release authorised by the Managing Director and Chief Executive Officer*

*Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia*